drugset / Trial / NCT00080288

Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD

NCT00080288

Phase 3 Completed 254 enrolled Cephalon
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to determine whether treatment with Armodafinil (CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness associated with chronic shift work sleep disorder (SWSD) by measuring mean sleep latency from the Multiple Sleep Latency Test (MSLT) (20 minutes) (average of 4 naps at 0200, 0400, 0600, and 0800) and by Clinical Global Impression of Change (CGI-C) ratings.

Timeline

Start
2004-03
Primary completion
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Armodafinil Small molecule 150 mg